Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 52 full-time employees. The firm is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer`s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. The company has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Website: vtvtherapeutics.com



Growth: Good revenue growth rate 100.0%, there is acceleration compared to average historical growth rates 12.5%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -266.7%. On average the margin is decreasing steadily. Gross margin is low, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 268.0% higher than minimum and 29.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -9.6x by EV / Sales multiple

Key Financials (Download financials)

Ticker: VTVT
Share price, USD:  (-6.4%)29.02
year average price 22.22  


year start price 17.87 2025-02-08

min close price 14.00 2025-08-08

max close price 41.19 2026-02-03

current price 29.02 2026-02-07
Common stocks: 81 483 600

Dividend Yield:  0.0%
EV / Sales: 395.9x
Margin (EBITDA LTM / Revenue): -266.7%
Fundamental value created in LTM:
Market Cap ($m): 2 365
Net Debt ($m): 11
EV (Enterprise Value): 2 376
Price to Book: 33.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-08-12globenewswire.com

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2025-03-20globenewswire.com

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

2025-03-17benzinga.com

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges

2024-08-08globenewswire.com

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

2024-07-29investorplace.com

Why Is vTv Therapeutics (VTVT) Stock Down 46% Today?

2024-07-26globenewswire.com

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

2024-06-24globenewswire.com

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

2023-06-15PRNewsWire

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-12 2024-11-12 2024-08-08 2024-05-09 2023-11-09 2023-08-11 2023-05-11 2022-11-10
acceptedDate 2025-11-06 16:32:16 2025-08-12 16:09:52 2025-03-20 16:28:20 2024-11-12 16:43:06 2024-08-08 16:20:11 2024-05-09 16:32:45 2024-03-13 07:58:44 2023-11-09 16:30:31 2023-08-11 16:40:54 2023-05-11 16:09:36 2023-03-06 17:30:33 2022-11-10 17:06:43 2022-03-29 17:29:44 2021-02-24 16:49:57
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 0 0 1M 0 0 1 000 000 0 0 9000 0 2M 0 4M 6M
costOfRevenue 0 0 0 0 23 000 22 000 0 22 000 23 000 0 0 0 0 11M
grossProfit 0 0 1M 0 -23 000 978 000 0 -22 000 -14 000 0 2M 0 4M -5M
grossProfitRatio 0 0 0 0 0.978 0 -1.556 0 1
researchAndDevelopmentExpenses 7M 4M 12M 3M 3M 3M 14M 3M 5M 4M 12M 3M 13M 11M
generalAndAdministrativeExpenses 4M 4M 14M 3M 4M 4M 12M 3M 3M 3M 12M 3M 12M 7M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 4M 4M 14M 3M 4M 4M 12M 3M 3M 3M 12M 3M 12M 7M
otherExpenses 0 0 0 0 0 -371 000 0 -3M 638 000 2M 0 0 0 -11M
operatingExpenses 11M 8M 25M 7M 7M 7M 26M 5M 8M 7M 25M 6M 26M 7M
costAndExpenses 11M 8M 25M 7M 7M 7M 26M 5M 8M 7M 25M 6M 26M 18M
interestIncome 399 000 275 000 2M 504 000 553 000 79 000 472 000 131 000 153 000 100 000 352 000 150 000 1000 12 000
interestExpense 5000 0 0 0 0 0 13 000 -4000 2000 -2M 15 000 8000 12 000 692 000
depreciationAndAmortization 2000 3000 89 000 22 000 23 000 22 000 90 000 22 000 23 000 2M 92 000 253 000 89 000 94 000
ebitda -10M -8M -23M -6M -6M -6M -26M -7M -7M -6M -25M -5M -18M -12M
ebitdaratio 0 0 0 0 -5.605 0 -798.444 0 0
operatingIncome -11M -8M -24M -7M -7M -6M -26M -7M -8M -7M -23M -6M -22M -12M
operatingIncomeRatio 0 0 0 0 -5.627 0 -888.889 0 0
totalOtherIncomeExpensesNet 354 000 341 000 2M 2M 746 000 -292 000 -464 000 -3M 638 000 2M -2M 221 000 4M -950 000
incomeBeforeTax -10M -7M -23M -5M -6M -6M -26M -7M -7M -6M -25M -5M -18M -13M
incomeBeforeTaxRatio 0 0 0 0 -5.919 0 -801.222 0 0
incomeTaxExpense 0 0 100 000 0 0 100 000 0 -3M -952 000 -1M 200 000 -1M 115 000 0
netIncome -9M -6M -18M -5M -5M -5M -20M -7M -6M -4M -19M -4M -13M -8M
netIncomeRatio 0 0 0 0 -4.865 0 -624.333 0 0
eps -1.08 -0.92 -3.2 -0.88 -0.81 -1.17 -9.71 -3.27 -0.069 -0.055 -9.98 -0.053 -8.29 -7.21
epsdiluted -1.08 -0.92 -0.88 -0.81 -1.17 -3.27 -0.069 -0.055 -0.053
weightedAverageShsOut 8M 7M 6M 5M 6M 4M 2M 2M 81M 81M 2M 80M 2M 1M
weightedAverageShsOutDil 8M 7M 6M 5M 6M 4M 2M 2M 81M 81M 2M 80M 2M 1M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-20 2024-03-13 2023-03-06 2022-03-29 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 2M 459 000 337 000 -11 000 -680 000
ebit -23M -26M -25M -18M -12M
nonOperatingIncomeExcludingInterest -2M 451 000 2M -4M 258 000
netIncomeFromContinuingOperations -23M -26M -25M -18M -13M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -18M -20M -19M -13M -8M
epsDiluted -3.2 -9.71 -9.98 -8.29 -7.21

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-12 2024-11-12 2024-08-08 2024-05-09 2023-11-09 2023-08-11 2023-05-11 2022-11-10
acceptedDate 2025-11-06 16:32:16 2025-08-12 16:09:52 2025-03-20 16:28:20 2024-11-12 16:43:06 2024-08-08 16:20:11 2024-05-09 16:32:45 2024-03-13 07:58:44 2023-11-09 16:30:31 2023-08-11 16:40:54 2023-05-11 16:09:36 2023-03-06 17:30:33 2022-11-10 17:06:43 2022-03-29 17:29:44 2021-02-24 16:49:57
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 99M 26M 37M 42M 46M 52M 9M 8M 13M 19M 12M 15M 13M 6M
shortTermInvestments 0 0 0 0 65 000 65 000 0 15 000 15 000 0 0 0 0 0
cashAndShortTermInvestments 99M 26M 37M 42M 46M 52M 9M 8M 13M 19M 12M 15M 13M 6M
netReceivables 0 0 62 000 242 000 306 000 981 000 102 000 0 0 0 12M 12M 57 000 158 000
inventory 0 0 0 0 -65 000 1 0 0 0 0 0 0 100 000 371 000
otherCurrentAssets 952 000 452 000 0 1M 433 000 636 000 0 2M 1M 2M 0 1M 35 000 0
totalCurrentAssets 99M 26M 38M 43M 46M 54M 11M 10M 14M 21M 27M 29M 16M 7M
propertyPlantEquipmentNet 38 000 74 000 153 000 206 000 258 000 311 000 361 000 412 000 461 000 509 000 556 000 558 000 680 000 849 000
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 4M 8M 8M 6M 6M 9M 7M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 0 0 0 0 0 -1 0 0 0 0 0 0 0 0
totalNonCurrentAssets 38 000 74 000 153 000 206 000 258 000 310 999 361 000 5M 8M 8M 6M 7M 10M 8M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0
totalAssets 99M 26M 38M 43M 46M 54M 11M 15M 22M 29M 33M 36M 25M 15M
accountPayables 10M 5M 939 000 0 7M 9M 4M -17 000 -17 000 0 2M 0 2M 2M
shortTermDebt 360 000 79 000 0 181 000 354 000 173 000 191 000 638 000 161 000 157 000 224 000 765 000 256 000 84 000
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 17 000 17 000 17 000 17 000 17 000 17 000 17 000 26 000 35 000 31 000
otherCurrentLiabilities 0 0 2M 6M -177 000 0 5M 10M 9M 8M 788 000 7M 3M 2M
totalCurrentLiabilities 10M 5M 5M 6M 7M 9M 11M 10M 9M 9M 8M 7M 8M 6M
longTermDebt 0 0 0 32 000 79 000 125 000 0 213 000 256 000 297 000 0 333 000 0 0
deferredRevenueNonCurrent 0 19M 19M 0 0 19M 19M 19M 19M 19M 19M 19M 0 1M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 -19M 0 -19M -19M 0 0 0 0 0
otherNonCurrentLiabilities 19M 79 000 100 000 19M 19M 19M 110 000 19M 19M 21M 684 000 44M 1M 3M
totalNonCurrentLiabilities 19M 19M 19M 19M 19M 19M 19M 19M 20M 39M 20M 45M 2M 5M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 32 000 79 000 169 000 213 000 256 000 125 000 338 000 378 000 417 000 454 000 492 000 541 000 676 000 831 000
totalLiabilities 29M 24M 24M 25M 26M 28M 30M 29M 29M 48M 27M 52M 10M 11M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 39 000 32 000 32 000 32 000 30 000 30 000 27 000 1M 1M 1M 27 000 1M 901 000 773 000
retainedEarnings -320M -311M -300M -296M -291M -286M -281M -281M -281M -274M -266M -267M -249M -290M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0 0 0 0 0 0 0 0 0
othertotalStockholdersEquity 390M 314M 311M 308M 307M 255M 254M 254M 249M
totalStockholdersEquity 71M 3M 12M 15M 16M 21M -25M -25M -25M -19M -11M -17M -10M -80M
totalEquity 71M 2M 14M 18M 20M 26M -19M -15M -6M 408 000 6M -17M 15M 4M
totalLiabilitiesAndStockholdersEquity 99M 26M 43M 46M 54M 15M 22M 29M 36M
minorityInterest 0 -357 000 2M 3M 4M 5M 6M 11M 19M 20M 17M 0 25M 84M
totalLiabilitiesAndTotalEquity 99M 26M 38M 43M 46M 54M 11M 15M 22M 29M 33M 36M 25M 15M
totalInvestments 0 0 0 0 65 000 65 000 0 4M 8M 8M 6M 6M 9M 7M
totalDebt 360 000 79 000 169 000 213 000 256 000 298 000 529 000 851 000 417 000 454 000 716 000 1M 932 000 915 000
netDebt -98M -26M -37M -41M -45M -52M -9M -7M -12M -18M -11M -14M -12M -5M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-20 2024-03-13 2023-03-06 2022-03-29 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 62 000 102 000 173 000 57 000 158 000
otherReceivables 0 0 12M 0 0
prepaids 1M 1M 3M 2M 939 000
totalPayables 939 000 4M 2M 2M 2M
otherPayables 0 0 0 0 0
accruedExpenses 3M 1M 4M 3M 3M
capitalLeaseObligationsCurrent 169 000 169 000 154 000 184 000 155 000
capitalLeaseObligationsNonCurrent 0 169 000 338 000 492 000 676 000
treasuryStock 0 0 0 0 0
additionalPaidInCapital 312M 256M 255M 238M 209M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT VTVT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-12 2024-11-12 2024-08-08 2024-05-09 2023-11-09 2023-08-11 2023-05-11 2022-11-10
acceptedDate 2025-11-06 16:32:16 2025-08-12 16:09:52 2025-03-20 16:28:20 2024-11-12 16:43:06 2024-08-08 16:20:11 2024-05-09 16:32:45 2024-03-13 07:58:44 2023-11-09 16:30:31 2023-08-11 16:40:54 2023-05-11 16:09:36 2023-03-06 17:30:33 2022-11-10 17:06:43 2022-03-29 17:29:44 2021-02-24 16:49:57
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -9M -7M -23M -7M -6M -5M -20M -9M -7M -6M -19M -5M -18M -13M
depreciationAndAmortization 2000 3000 89 000 22 000 23 000 22 000 90 000 22 000 23 000 22 000 92 000 24 000 89 000 94 000
deferredIncomeTax 0 0 0 0 0 0 0 0 -4M 0 0 0 0 -4M
stockBasedCompensation 0 930 000 3M 853 000 859 000 220 000 2M 433 000 399 000 343 000 0 338 000 2M 1M
changeInWorkingCapital -513 000 1M -5M 3M -1M -2M 4M -48 000 1M 2M 5M -4M 35 000 -3M
accountsReceivables 0 0 40 000 64 000 675 000 -879 000 71 000 0 0 173 000 -116 000 20 000 101 000 -153 000
inventory 0 0 0 0 0 0 0 0 0 0 0 0 -889 000 -2M
accountsPayables 0 1M 0 -3M 0 -2M 3M 500 000 738 000 1M -856 000 0 2M -997 000
otherWorkingCapital -513 000 393 000 -5M 5M -2M 461 000 1M -548 000 522 000 -1M 6M -4M -1M 420 000
otherNonCashItems 4M -66 000 -10000 -3M -193 000 2M -5M 3M 3M -2M -2M -220 000 -4M 380 000
netCashProvidedByOperatingActivities -5M -5M -25M -6M -7M -7M -19M -5M -6M -5M -15M -9M -19M -18M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 0 0 0 0 -21 000 0 0 0
acquisitionsNet 0 0 0 0 0 0 4M 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 4M 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 0 0 0 0 0 0
debtRepayment 0 0 0 0 -191 000 -93 000 0 -224 000 -219 000
commonStockIssued 0 9000 2M 0 50M 0 0 12M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 1M 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 78M -51 000 2M 0 50M 566 000 -1M 0 7M
netCashUsedProvidedByFinancingActivities 78M -42 000 2M 0 50M 473 000 1M 12M 6M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 73M -5M 27M -4M -7M 43M -3M -4M -6M 7M -1M -3M 8M 1M
cashAtEndOfPeriod 99M 26M 37M 42M 46M 52M 9M 8M 13M 19M 12M 15M 13M 6M
cashAtBeginningOfPeriod 26M 31M 9M 46M 52M 9M 12M 13M 19M 12M 13M 18M 6M 4M
operatingCashFlow -5M -5M -25M -6M -7M -7M -19M -5M -6M -5M -15M -9M -19M -18M
capitalExpenditure 0 0 0 0 0 0 0 0 0 0 -21 000 0 0 0
freeCashFlow -5M -5M -25M -6M -7M -7M -19M -5M -6M -5M -15M -9M -19M -18M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-20 2024-03-13 2023-03-06 2022-03-29 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 -4M 0 0 0
netCashProvidedByInvestingActivities 0 4M -21 000 0 0
netDebtIssuance -191 000 -33 000 -808 000 172 000 -5M
longTermNetDebtIssuance 0 -33 000 -808 000 172 000 -5M
shortTermNetDebtIssuance -191 000 0 0 0 0
netStockIssuance 53M 12M 15M 27M 24M
netCommonStockIssuance 53M 12M 15M 27M 24M
commonStockIssuance 53M 12M 15M 27M 24M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 47 000 0
netCashProvidedByFinancingActivities 53M 12M 14M 27M 19M
incomeTaxesPaid 100 000 0 0 115 000 0
interestPaid 2000 0 0 11 000 0

Earning call transcript

SEC forms

Show financial reports only

SEC form 8
2025-12-19 17:10 ET
vTv Therapeutics published news for 2025 q3
SEC form 8
2025-12-19 17:10 ET
vTv Therapeutics published news for 2025 q3
SEC form 10
2025-11-06 16:32 ET
vTv Therapeutics reported for 2025 q3
SEC form 8
2025-11-06 16:26 ET
vTv Therapeutics published news for 2025 q3
SEC form 8
2025-11-06 16:26 ET
vTv Therapeutics reported for 2025 q3
SEC form 8
2025-09-02 13:00 ET
vTv Therapeutics published news for 2025 q2
SEC form 8
2025-09-02 13:00 ET
vTv Therapeutics published news for 2025 q2
SEC form 8
2025-09-02 13:00 ET
vTv Therapeutics published news for 2025 q2
SEC form 8
2025-09-02 13:00 ET
vTv Therapeutics published news for 2025 q2
SEC form 8
2025-09-02 13:00 ET
vTv Therapeutics published news for 2025 q2
SEC form 10
2025-08-12 20:09 ET
vTv Therapeutics reported for 2025 q2
SEC form 8
2025-08-12 20:05 ET
vTv Therapeutics published news for 2025 q2
SEC form 8
2025-08-12 20:05 ET
vTv Therapeutics reported for 2025 q2
SEC form 8
2025-05-16 13:05 ET
vTv Therapeutics published news for 2025 q1
SEC form 8
2025-05-16 13:05 ET
vTv Therapeutics published news for 2025 q1
SEC form 10
2025-05-15 20:07 ET
vTv Therapeutics published news for 2025 q1
SEC form 10
2025-05-15 00:00 ET
vTv Therapeutics published news for 2025 q1
SEC form 8
2025-05-15 00:00 ET
vTv Therapeutics published news for 2025 q1
SEC form 8
2025-05-15 00:00 ET
vTv Therapeutics reported for 2025 q1
SEC form 8
2025-03-31 20:30 ET
vTv Therapeutics published news for 2024 q4
SEC form 8
2025-03-31 20:30 ET
vTv Therapeutics published news for 2024 q4
SEC form 10
2025-03-20 20:28 ET
vTv Therapeutics published news for 2024 q4
SEC form 10
2025-03-20 00:00 ET
vTv Therapeutics published news for 2024 q4
SEC form 8
2025-03-20 00:00 ET
vTv Therapeutics published news for 2024 q4
SEC form 8
2025-03-20 00:00 ET
vTv Therapeutics reported for 2024 q4
SEC form 8
2025-03-17 13:03 ET
vTv Therapeutics published news for 2024 q4
SEC form 8
2025-03-17 13:03 ET
vTv Therapeutics published news for 2024 q4
SEC form 10
2024-11-12 16:43 ET
vTv Therapeutics reported for 2024 q3
SEC form 8
2024-11-12 16:26 ET
vTv Therapeutics published news for 2024 q3
SEC form 8
2024-11-12 16:26 ET
vTv Therapeutics reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
vTv Therapeutics reported for 2024 q3
SEC form 10
2024-08-08 00:00 ET
vTv Therapeutics reported for 2024 q2
SEC form 8
2024-08-08 00:00 ET
vTv Therapeutics published news for 2024 q2
SEC form 8
2024-08-08 00:00 ET
vTv Therapeutics reported for 2024 q2
SEC form 10
2024-05-09 00:00 ET
vTv Therapeutics published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
vTv Therapeutics published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
vTv Therapeutics reported for 2024 q1
SEC form 10
2024-03-13 00:00 ET
vTv Therapeutics published news for 2023 q4
SEC form 8
2024-03-13 00:00 ET
vTv Therapeutics published news for 2023 q4
SEC form 8
2024-03-13 00:00 ET
vTv Therapeutics reported for 2023 q4
SEC form 10
2023-11-09 16:30 ET
vTv Therapeutics reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
vTv Therapeutics reported for 2023 q3
SEC form 10
2023-08-11 16:40 ET
vTv Therapeutics reported for 2023 q2
SEC form 6
2023-08-11 16:36 ET
vTv Therapeutics reported for 2023 q2
SEC form 10
2023-08-11 00:00 ET
vTv Therapeutics reported for 2023 q2
SEC form 8
2023-08-11 00:00 ET
vTv Therapeutics reported for 2023 q2
SEC form 6
2023-07-20 16:22 ET
vTv Therapeutics published news for 2023 q2
SEC form 6
2023-06-26 16:24 ET
vTv Therapeutics published news for 2023 q1
SEC form 6
2023-06-08 16:24 ET
vTv Therapeutics published news for 2023 q1
SEC form 10
2023-05-11 16:09 ET
vTv Therapeutics reported for 2023 q1
SEC form 6
2023-05-11 16:06 ET
vTv Therapeutics reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
vTv Therapeutics reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
vTv Therapeutics reported for 2023 q1
SEC form 10
2023-03-06 17:30 ET
vTv Therapeutics reported for 2022 q4
SEC form 6
2023-03-06 17:29 ET
vTv Therapeutics reported for 2022 q4
SEC form 6
2023-03-06 16:30 ET
vTv Therapeutics published news for 2022 q4
SEC form 10
2023-03-06 00:00 ET
vTv Therapeutics reported for 2022 q4
SEC form 8
2023-03-06 00:00 ET
vTv Therapeutics reported for 2022 q4
SEC form 6
2023-02-01 17:06 ET
vTv Therapeutics published news for 2022 q4
SEC form 6
2023-01-06 17:20 ET
vTv Therapeutics published news for 2022 q4
SEC form 6
2022-12-23 16:35 ET
vTv Therapeutics published news for 2022 q3
SEC form 6
2022-12-13 17:00 ET
vTv Therapeutics published news for 2022 q3
SEC form 6
2022-12-13 09:02 ET
vTv Therapeutics published news for 2022 q3
SEC form 10
2022-11-10 17:06 ET
vTv Therapeutics reported for 2022 q3
SEC form 6
2022-11-10 16:57 ET
vTv Therapeutics reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
vTv Therapeutics reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
vTv Therapeutics reported for 2022 q3
SEC form 6
2022-08-18 19:00 ET
vTv Therapeutics published news for 2022 q2
SEC form 6
2022-08-17 09:40 ET
vTv Therapeutics published news for 2022 q2
SEC form 10
2022-08-15 18:15 ET
vTv Therapeutics reported for 2022 q2
SEC form 6
2022-08-15 18:15 ET
vTv Therapeutics reported for 2022 q2
SEC form 6
2022-08-15 17:47 ET
vTv Therapeutics published news for 2022 q2
SEC form 10
2022-08-15 00:00 ET
vTv Therapeutics published news for
SEC form 8
2022-08-15 00:00 ET
vTv Therapeutics reported for 2022 q2
SEC form 6
2022-07-27 07:26 ET
vTv Therapeutics published news for 2022 q2
SEC form 6
2022-07-25 07:11 ET
vTv Therapeutics published news for 2022 q2
SEC form 6
2022-07-15 16:37 ET
vTv Therapeutics published news for 2022 q2
SEC form 6
2022-06-10 20:31 ET
vTv Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 16:10 ET
vTv Therapeutics published news for 2022 q1
SEC form 6
2022-06-03 16:01 ET
vTv Therapeutics published news for 2022 q1
SEC form 6
2022-06-01 07:38 ET
vTv Therapeutics published news for 2022 q1
SEC form 6
2022-05-12 06:07 ET
vTv Therapeutics published news for 2022 q1
SEC form 10
2022-05-12 06:05 ET
vTv Therapeutics reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
vTv Therapeutics reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
vTv Therapeutics reported for 2022 q1
SEC form 6
2022-05-02 17:20 ET
vTv Therapeutics published news for 2022 q1
SEC form 6
2022-04-15 16:31 ET
vTv Therapeutics published news for 2022 q1
SEC form 6
2022-04-05 17:21 ET
vTv Therapeutics published news for 2022 q1
SEC form 6
2022-04-05 16:08 ET
vTv Therapeutics published news for 2022 q1
SEC form 10
2022-03-29 17:29 ET
vTv Therapeutics published news for 2021 q4
SEC form 6
2022-03-29 17:24 ET
vTv Therapeutics published news for 2021 q4
SEC form 10
2022-03-29 00:00 ET
vTv Therapeutics published news for 2021 q4
SEC form 8
2022-03-29 00:00 ET
vTv Therapeutics published news for 2021 q4
SEC form 6
2022-03-03 17:23 ET
vTv Therapeutics published news for 2021 q4
SEC form 6
2022-02-18 16:27 ET
vTv Therapeutics published news for 2021 q4
SEC form 6
2021-12-06 17:35 ET
vTv Therapeutics published news for 2021 q3
SEC form 6
2021-12-02 17:17 ET
vTv Therapeutics published news for 2021 q3
SEC form 6
2021-11-09 08:46 ET
vTv Therapeutics published news for 2021 q3
SEC form 10
2021-11-09 08:39 ET
vTv Therapeutics published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
vTv Therapeutics published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
vTv Therapeutics published news for 2021 q3
SEC form 6
2021-10-20 09:00 ET
vTv Therapeutics published news for 2021 q3
SEC form 10
2021-08-04 16:46 ET
vTv Therapeutics published news for 2021 q2
SEC form 6
2021-08-04 16:35 ET
vTv Therapeutics published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
vTv Therapeutics published news for 2021 q2
SEC form 6
2021-06-25 16:35 ET
vTv Therapeutics published news for 2021 q1
SEC form 6
2021-05-05 16:37 ET
vTv Therapeutics published news for 2021 q1
SEC form 10
2021-05-05 16:30 ET
vTv Therapeutics published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
vTv Therapeutics published news for 2021 q1
SEC form 6
2021-03-18 07:30 ET
vTv Therapeutics published news for 2020 q4
SEC form 6
2021-03-08 16:17 ET
vTv Therapeutics published news for 2020 q4
SEC form 6
2021-02-24 16:55 ET
vTv Therapeutics published news for 2020 q4
SEC form 10
2021-02-24 16:49 ET
vTv Therapeutics published news for 2020 q4
SEC form 6
2021-01-21 16:05 ET
vTv Therapeutics published news for 2020 q4
SEC form 6
2021-01-14 17:15 ET
vTv Therapeutics published news for 2020 q4
SEC form 6
2020-12-30 16:30 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-12-17 16:30 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-12-15 07:51 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-12-10 16:30 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-11-24 16:30 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-11-17 16:30 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-11-05 16:53 ET
vTv Therapeutics published news for 2020 q3
SEC form 10
2020-11-05 16:32 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-10-26 07:00 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-10-02 17:00 ET
vTv Therapeutics published news for 2020 q3